TIMOTHY SHANNON

Corporate Board Profile

Tech Score: 0/100

Celldex Therapeutics, Inc.

Filing Date	Source Excerpt
2009-11-06	Timothy M. Shannon, M.D. became a director of Celldex upon the consummation of the merger between Celldex and CuraGen in October 2009. He had been a CuraGen Director since his appointment as CuraGen's President and Chief Executive Officer in September 2007. The Board of Directors is currently managed by a nine member Board of Directors, each of whom is nominated for re-election at the Annual Meeting. With the exception of Messrs. Marucci and Shannon, each of the current directors and nominees are "independent" as that term is defined in the applicable NASDAQ listing standards. The Director Compensation table does not list compensation for Mr. Shannon as a director.

Filing Date

Source Excerpt

2009-11-06

Timothy M. Shannon, M.D. became a director of Celldex upon the consummation of the merger between Celldex and CuraGen in October 2009. He had been a CuraGen Director since his appointment as CuraGen's President and Chief Executive Officer in September 2007. The Board of Directors is currently managed by a nine member Board of Directors, each of whom is nominated for re-election at the Annual Meeting. With the exception of Messrs. Marucci and Shannon, each of the current directors and nominees are "independent" as that term is defined in the applicable NASDAQ listing standards. The Director Compensation table does not list compensation for Mr. Shannon as a director.

Data sourced from SEC filings. Last updated: 2025-10-12